Key result
Targeting oxidative and inflammatory pathways offers potential therapeutic strategy in diabetic cardiomyopathy.
Why the study?
The pathogenesis of diabetic cardiomyopathy is complex and not fully elucidated, leaving no specific and effective treatment.
This review highlights the complex interplay of oxidative stress signaling pathways in diabetic cardiomyopathy, identifying potential targets for future therapies.
Supports targeting Nrf2/NF-κB/Sirt1 in diabetic cardiomyopathy; leaves open clinical translation pending interventional trials.
As a serious cardiovascular complication, diabetic cardiomyopathy (DCM) refers to diabetes-related changes in myocardial structure and function, which is obviously different from those cardiomyopathy secondary to hypertension, coronary heart disease, and valvular disease. The clinical features of DCM are left ventricular hypertrophy, myocardial fibrosis, and impaired diastolic function. DCM will lead to cardiac dysfunction, eventually progress to cardiac arrhythmia, heart failure, and sudden cardiac death. At present, the pathogenesis of DCM is complex and not fully elucidated, and oxidative stress (OS), inflammatory response, glucolipid metabolism disorder, etc., are considered as the potential pathophysiological mechanisms. As a consequence, there is no specific and effective treatment for DCM. OS refers to the imbalance between reactive oxygen species (ROS) accumulation and scavenging, oxidation, and antioxidants in vivo, which is widely studied in DCM. Numerous studies have pointed out that regulating the OS signaling pathways and reducing the generation and accumulation of ROS are potential directions for the treatment of DCM. This review summarizes the major OS signaling pathways that are related to the pathogenesis of DCM, providing ideas about further research and therapy.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2022) conducted a review in Diabetic Cardiomyopathy. Oxidative stress was evaluated. Oxidative stress and inflammatory responses interact to promote cardiac dysfunction in diabetic cardiomyopathy, with pathways like Nrf2, NF-κB, and Sirt1 serving as potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: